Jiangsu Recbio Technology Co., Ltd. Class H (HK:2179) has released an update.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Jiangsu Recbio Technology Co., Ltd. has successfully completed the enrollment for the Phase III clinical trial of its new shingles vaccine, REC610. This vaccine, designed for adults over 40, is being tested for its efficacy and safety at multiple centers in China. With the market currently dominated by GlaxoSmithKline’s Shingrix, there is significant demand for a domestic alternative like REC610.
For further insights into HK:2179 stock, check out TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue